Fischer A, Bastian S, Cogliatti S, et al. Ibrutinib-induced rapid response in chemotherapy-refractory Richter’s syndrome. Hematol Oncol., 2018; 36: 370–371.
Ding W, LaPlant BR, Call TG, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood, 2017; 129: 3419–3427.
Allan JN, Furman RR. Current trends in the management of Richter’s syndrome. Int J Hematol Oncol., 2018; 7(4): IJH09.